Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

NeoGenomics, Inc. - Common Stock (NQ:NEO)

6.200 -0.040 (-0.64%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about NeoGenomics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
NeoGenomics, Progyny, Repligen, Revvity, and Waters Corporation Shares Are Soaring, What You Need To Know
A number of stocks jumped in the afternoon session after markets continued to rally amid growing speculation of an impending interest rate cut by the Federal Reserve. Following a favorable Consumer... 
Via StockStory
Topics Economy
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeoGenomics, Inc. - NEO
From Pomerantz LLP
Via GlobeNewswire
AMN Healthcare Services, NeoGenomics, Acadia Healthcare, BrightSpring Health Services, and Repligen Shares Are Soaring, What You Need To Know
A number of stocks jumped in the afternoon session after positive inflation data fueled hopes for an interest rate cut by the Federal Reserve. The latest Consumer Price Index (CPI) report showed... 
Via StockStory
Topics Bonds Economy Stocks
Earnings Scheduled For August 12, 2025
 
Via Benzinga
NEO Q2 Deep Dive: Guidance Reset Amid Pharma Weakness, Delayed Product Launches
Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) fell short of the market’s revenue expectations in Q2 CY2025, but sales rose 10.2% year on year to $181.3 million. The company’s full-year... 
Via StockStory
Earnings Outlook For NeoGenomics
 
Via Benzinga
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of NeoGenomics, Inc. - NEO
From Pomerantz LLP
Via GlobeNewswire
Why NeoGenomics (NEO) Stock Is Trading Up Today
Shares of oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) jumped 4.8% in the afternoon session after news of a significant insider purchase by a key executive. The move followed the... 
Via StockStory
Earnings Scheduled For July 29, 2025
 
Via Benzinga
1 Small-Cap Stock with Exciting Potential and 2 We Ignore
Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and their stock prices) often stay small... 
Via StockStory
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeoGenomics, Inc. - NEO
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeoGenomics, Inc. - NEO
From Pomerantz LLP
Via GlobeNewswire
A Glimpse Into The Expert Outlook On NeoGenomics Through 3 Analysts
 
Via Benzinga
NeoGenomics Launches PanTracer LBx, Expanding Access to Comprehensive Genomic Profiling with Liquid Biopsy
From NeoGenomics, Inc.
Via Business Wire
Why NeoGenomics (NEO) Shares Are Falling Today
Shares of oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) fell 20.2% in the morning session after the company reported second-quarter results that included a significant cut to its... 
Via StockStory
Topics Lawsuit
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
Whirlpool Posts Downbeat Earnings, Joins Harmonic, Stanley Black & Decker And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
NeoGenomics (NASDAQ:NEO) Misses Q2 Sales Targets, Stock Drops 15.8%
Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) missed Wall Street’s revenue expectations in Q2 CY2025, but sales rose 10.2% year on year to $181.3 million. The company’s full-year... 
Via StockStory
NeoGenomics Reports Second Quarter 2025 Results
From NeoGenomics, Inc.
Via Business Wire
NeoGenomics (NEO) Reports Q2: Everything You Need To Know Ahead Of Earnings
Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) will be reporting earnings this Tuesday before market hours. Here’s what to expect. 
Via StockStory
Topics Artificial Intelligence
3 of Wall Street’s Favorite Stocks We’re Skeptical Of
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because... 
Via StockStory
Moderna, Lantheus, Centene, AMN Healthcare Services, and NeoGenomics Shares Plummet, What You Need To Know
A number of healthcare stocks fell in the afternoon session after several negative developments weighed on the sector. Weakness in managed care providers was a significant factor, with companies like... 
Via StockStory
Topics Lawsuit World Trade
3 Stocks Under $10 We’re Skeptical Of
Stocks trading in the $1-10 range are generally smaller players with less risk than their penny stock counterparts. But that doesn’t mean the underlying businesses are cheap, and we advise caution as... 
Via StockStory
Q1 Earnings Highlights: NeoGenomics (NASDAQ:NEO) Vs The Rest Of The Testing & Diagnostics Services Stocks
As the Q1 earnings season wraps, let’s dig into this quarter’s best and worst performers in the testing & diagnostics services industry, including NeoGenomics (NASDAQ:NEO) and its peers. 
Via StockStory
NeoGenomics, RadNet, Pediatrix Medical Group, Penumbra, and Neogen Shares Plummet, What You Need To Know
A number of stocks fell in the afternoon session after the U.S. administration announced a sharp escalation in trade tensions by threatening new tariffs on Canada. 
Via StockStory
Topics ETFs Stocks World Trade
3 Russell 2000 Stocks with Questionable Fundamentals
The Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on. However, these companies often come with higher... 
Via StockStory
Topics Artificial Intelligence
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zeo Energy Corp. - ZEO
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zeo Energy Corp. - ZEO
From Pomerantz LLP
Via GlobeNewswire
NeoGenomics to Report Second Quarter 2025 Financial Results on July 29, 2025
From NeoGenomics, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.